Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) experienced a dramatic stock surge, climbing 94.45% to $0.8867 on substantial trading volume following the announcement of a securities purchase agreement with institutional investors. The agreement involves the sale of over 5 million American Depositary Shares at $0.48 each, along with warrants for further ADS purchases. Scinai is focused on developing innovative immunology therapies and also operates a contract development and manufacturing organization, expanding its reach in the biopharmaceutical sector.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.investorideas.com/news/2026/biotech/04241-scinai-immunotherapeutics-top-gainer-financing.asp
